fecal microbiota transplantation

$Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

By MedXY 08/27/2026

This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT's potential as a safe and effective treatment option.

Gastroenterology Infectious Diseases news

Evaluating the Necessity of Live Microbes in Fecal Microbiota Transplantation for C. difficile Recurrence: Insights from a Non-Inferiority Trial

By MedXY 10/18/2025

This study investigates whether sterile lyophilised fecal filtrate is as effective as traditional donor stool in preventing recurrent C. difficile infection, highlighting the importance of live microbes in treatment efficacy.

Clinical Updates Gastroenterology news Transplantation

The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis

By MedXY 09/20/2025

The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.

Neurology Pediatrics Specialties Transplantation

Exploring Fecal Microbiota Transplantation for Autism Spectrum Disorder: Efficacy, Safety, and Future Directions

By MedXY 08/18/2025

Fecal microbiota transplantation (FMT) shows promise in improving gastrointestinal and behavioral symptoms in children with autism spectrum disorder (ASD), but further rigorous trials are needed to confirm its efficacy and optimize protocols.

Clinical Updates Gastroenterology news Specialties Transplantation

Consecutive Fecal Microbiota Transplantation in MASLD: Insights from a Double-Blind Randomized Controlled Trial

By MedXY 08/07/2025

A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may be crucial.